Jaguar health reports approval of all proposals at march 2025 special meeting of stockholders

Jaguar expects first results in q2 2025 of proof-of-concept investigator-initiated trials of crofelemer for the rare diseases short bowel syndrome with intestinal failure and microvillus inclusion disease fda meeting expected in q2 2025 on the statistically significant results of the phase 3 ontarget trial of crofelemer in the prespecified subgroup of patients with breast cancer san francisco, ca / access newswire / march 13, 2025 / jaguar health, inc. (nasdaq:jagx) ("jaguar" or the "company") today announced the voting results of the company's special meeting of stockholders held on march 13, 2025 (the "special meeting"). two proposals were submitted to and approved by the stockholders of the company at the special meeting.
JAGX Ratings Summary
JAGX Quant Ranking